These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Zinc Metallochaperones as Mutant p53 Reactivators: A New Paradigm in Cancer Therapeutics. Kogan S; Carpizo DR Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29843463 [TBL] [Abstract][Full Text] [Related]
7. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Willis A; Jung EJ; Wakefield T; Chen X Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206 [TBL] [Abstract][Full Text] [Related]
8. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological activation of p53 in cancer cells. Athar M; Elmets CA; Kopelovich L Curr Pharm Des; 2011; 17(6):631-9. PubMed ID: 21391904 [TBL] [Abstract][Full Text] [Related]
10. Mutant p53 reactivation by small molecules makes its way to the clinic. Bykov VJ; Wiman KG FEBS Lett; 2014 Aug; 588(16):2622-7. PubMed ID: 24768524 [TBL] [Abstract][Full Text] [Related]
11. Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy. Bykov VJ; Zhang Q; Zhang M; Ceder S; Abrahmsen L; Wiman KG Front Oncol; 2016; 6():21. PubMed ID: 26870698 [TBL] [Abstract][Full Text] [Related]
12. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393 [TBL] [Abstract][Full Text] [Related]
13. Targeting mutant p53 for efficient cancer therapy. Bykov VJN; Eriksson SE; Bianchi J; Wiman KG Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642 [TBL] [Abstract][Full Text] [Related]
14. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition. Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507 [TBL] [Abstract][Full Text] [Related]
15. Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies. Kaur RP; Vasudeva K; Kumar R; Munshi A Curr Pharm Des; 2018; 24(30):3566-3575. PubMed ID: 30255744 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Wiman KG Oncogene; 2010 Jul; 29(30):4245-52. PubMed ID: 20498645 [TBL] [Abstract][Full Text] [Related]
18. p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Song H; Hollstein M; Xu Y Nat Cell Biol; 2007 May; 9(5):573-80. PubMed ID: 17417627 [TBL] [Abstract][Full Text] [Related]
19. Targeting Oncogenic Mutant p53 for Cancer Therapy. Parrales A; Iwakuma T Front Oncol; 2015; 5():288. PubMed ID: 26732534 [TBL] [Abstract][Full Text] [Related]
20. Dominant-negative p53 mutant R248Q increases the motile and invasive activities of oral squamous cell carcinoma cells. Nakazawa S; Sakata KI; Liang S; Yoshikawa K; Iizasa H; Tada M; Hamada JI; Kashiwazaki H; Kitagawa Y; Yamazaki Y Biomed Res; 2019; 40(1):37-49. PubMed ID: 30787262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]